» Authors » Matthew C Exline

Matthew C Exline

Explore the profile of Matthew C Exline including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 79
Citations 3896
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Frutos A, Cleary S, Reeves E, Ahmad H, Price A, Self W, et al.
MMWR Morb Mortal Wkly Rep . 2025 Feb; 74(6):83-90. PMID: 40014791
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits...
2.
Khan A, Zhu Y, Babcock H, Busse L, Duggal A, Exline M, et al.
Vaccine . 2025 Jan; 48:126806. PMID: 39884913
Background: Understanding similarities and differences between hesitancy for influenza and COVID-19 vaccines could facilitate strategies to improve public receptivity toward vaccination. Methods: We compared hesitancy for COVID-19 vaccines during the...
3.
Lewis N, Harker E, Grant L, Zhu Y, Grijalva C, Chappell J, et al.
Clin Infect Dis . 2024 Nov; PMID: 39607747
Background: clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods: A multicenter US observational sentinel surveillance network prospectively enrolled...
4.
Lewis N, Harker E, Leis A, Zhu Y, Talbot H, Grijalva C, et al.
Vaccine . 2024 Nov; 43(Pt 2):126492. PMID: 39515195
Background: In test-negative studies of vaccine effectiveness (VE), including patients with co-circulating, vaccine-preventable, respiratory pathogens in the control group for the pathogen of interest can introduce a downward bias on...
5.
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, et al.
Influenza Other Respir Viruses . 2024 Nov; 18(11):e70027. PMID: 39496339
Background: Assessments of COVID-19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID-19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain...
6.
Ma K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, et al.
Clin Infect Dis . 2024 Aug; PMID: 39107255
Background: Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as...
7.
Ma K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, et al.
medRxiv . 2024 Jun; PMID: 38883802
Background: Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to...
8.
Di H, Pusch E, Jones J, Kovacs N, Hassell N, Sheth M, et al.
Vaccines (Basel) . 2024 May; 12(5). PMID: 38793756
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into numerous lineages with unique spike mutations and caused multiple epidemics domestically and globally. Although COVID-19 vaccines are available, new variants...
9.
Pannu S, Exline M, Bednash J, Englert J, Diaz P, Bartlett A, et al.
Trials . 2024 May; 25(1):328. PMID: 38760804
Background: The SARS CoV-2 pandemic has resulted in more than 1.1 million deaths in the USA alone. Therapeutic options for critically ill patients with COVID-19 are limited. Prior studies showed...
10.
Mart M, Boehm L, Kiehl A, Gong M, Malhotra A, Owens R, et al.
Lancet Respir Med . 2024 May; 12(8):599-607. PMID: 38701817
Background: Delirium is common during critical illness and is associated with long-term cognitive impairment and disability. Antipsychotics are frequently used to treat delirium, but their effects on long-term outcomes are...